Docetaxel (Taxotere®)

Common name: Docetaxel
Brand name: Taxotere®
 

What is Docetaxel?

Docetaxel is a chemotherapy drug used in combination with a corticosteroid (such as prednisone or prednisolone) to treat androgen-independent metastatic prostate cancer.


How is Docetaxel administered?

Docetaxel is administered by injection.

What are possible side effects of this treatment?

Everyone responds differently to chemotherapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received docetaxel. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Anemia
  • Bruising / bleeding
  • Changes to taste
  • Diarrhea
  • Fatigue
  • Fluid retention
  • Hair loss
  • Infection
  • Increase in production of tears
  • Loss of appetite
  • Mouth sores
  • Nausea / vomiting
  • Numbness, burning, tingling in hands and feet
  • Pain in joints
  • Rash

Is Docetaxel covered in my province or territory?*

Docetaxel is covered by provincial drug programs in:
 
•    Alberta
•    British Columbia
•    Nova Scotia
•    Ontario
•    Quebec
•    Saskatchewan
•    Yukon
 
Docetaxel is not covered by provincial drug programs in:
 
•    New Brunswick
•    Newfoundland & Labrador
•    Prince Edward Island
•    Nunavut
•    Northwest Territories

Unknown if docetaxel is covered by provincial drug programs in:
•    Manitoba

*Source: http://drugcoverage.ca/en-ca/search-results.aspx?ID=20468

 
    Last Reviewed: July 2017




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Université de Sherbrooke Researchers’ Findings Published in Cancer Research

Sherbrooke, November 16, 2017 – Prostate cancer, the most common cancer in men, affects one out of seven Canadian men.
More

12 innovative Canadian prostate cancer researchers set out to make new Discoveries

Toronto, ON – September 28, 2017: 12 forward-thinking Canadian prostate cancer researchers have been rewarded for their innovation with Movember Discovery Grants.
More

Gray Tools '2017 Together We Are Stronger' campaign a success in creating awareness and raising funds for prostate cancer

BRAMPTON, Ontario, Sept 26, 2017 (GLOBE NEWSWIRE) -- Gray Tools Canada Inc, in cooperation with Prostate Cancer Canada, is proud to announce that its “2017 Together We Are Stronger” initiative raised $4,000, which will go directly towards funding valuable research that is needed to improve the way we diagnose, treat, and support men living with the disease.
More


Click here for news archive